The UK biotech unveils Phase II data showing an ability to reduce severity of mild-to-moderate AA, with full hair restoration in some patients. If approved, STS-01 will compete with Olumiant and Litfulo.

US FDA Principal Deputy Commissioner Namandjé Bumpus recently attended a biotech-themed roundtable with the Senate Select Committee on Intelligence and national security officials as Congress’ pulls the FDA into its worries about Chinese influence of the pharma industry.

A material shift in China derisking discussions by big biopharma against the backdrop of the proposed US BIOSECURE Bill is seen presenting opportunities for Syngene, though the tight US biotech funding environment dampened demand for the Indian CRDMO’s R&D services in Q4.

CRDMO CXOs sketch a promising landscape for the Indian industry, highlighting technology, scale and talent, particularly millennials and Gen Z, as key factors in a SWOT analysis - while cautioning that a global ‘China plus one’ strategy could turn to a ‘India plus one’ too.